DuPont received $1,158 million from business sales in the first half, exceeding its $1,022 million increase in cash, including restricted cash—money set aside for specified uses. Business-sale proceeds were therefore essential to the reported cash increase, despite stronger earnings from continuing operations. That distinction matters because asset sales provide a finite source of funding for shareholder returns. The smaller DuPont combines healthcare and water products with construction and industrial materials, whose demand remains sensitive to economic conditions. 10-Q, cash-flow statement, p. 9; Note 1, p. 13
1. Cash rose while the asset base shrank
The Aramids sale improved liquidity while leaving DuPont with fewer operating assets and more investment exposure.
1-1. The cash increase includes a business leaving the group
Read cash alongside the investments received in the sale, rather than treating the increase as operating cash generation. Dollar amounts shown as $M are in millions.
| Item ($M) | Dec. 31, 2025 | June 30, 2026 | Change |
|---|---|---|---|
| Cash and equivalents | 715 | 1,740 | +143.4% |
| Accounts and notes receivable, net | 1,669 | 1,751 | +4.9% |
| Inventories | 1,172 | 1,210 | +3.2% |
| Property, plant and equipment, net | 3,464 | 3,379 | −2.5% |
| Other intangible assets | 2,936 | 2,789 | −5.0% |
| Goodwill | 7,915 | 7,840 | −0.9% |
| Investments and noncurrent receivables | 432 | 981 | +127.1% |
| Total assets | 21,575 | 21,061 | −2.4% |
Source: 10-Q, balance sheets, p. 8. Percentage changes equal the June balance divided by the December balance, minus one.
Cash and equivalents in this table increased by $1,025M. The opening paragraph’s $1,022M increase uses the broader cash-flow measure, which also includes restricted cash and cash held by discontinued operations. That broader balance rose from $760M to $1,782M. The different amounts reflect different coverage, not conflicting cash totals. 10-Q, pp. 8–9
Assets classified as discontinued operations—businesses being disposed of and reported separately—were $1,856M at year-end and were no longer on the balance sheet after the Aramids sale. That year-end balance is not the assets’ value at closing. DuPont received an Arclin equity interest initially valued at $325M. Its $300M contractual note receivable, a promise of future payment, was initially recorded at $183M fair value, reflecting market interest rates for similar credit facilities and the note’s duration. Neither investment is immediately available cash. 10-Q, Note 3, pp. 16–17
Receivables and inventory absorbed cash, but their balance-sheet movements also include effects beyond customer collections and purchases. Intangible assets declined alongside amortization, the accounting expense that spreads their cost over time. The filing does not provide a complete standalone explanation for every asset movement.
1-2. Debt fell, but legal obligations increased
Borrowings, including finance leases within long-term debt, fell from $3,194M to $3,125M. Trade payables fell from $995M to $978M, while accrued current obligations rose from $882M to $970M. Indemnification liabilities—amounts owed under agreements to cover other parties’ costs—rose from $614M to $723M; these are already included in the reported liability categories and should not be added again. 10-Q, pp. 8, 29–30
No long-term debt was due within one year. The year-end maturity schedule identifies $1,350M due in 2028, approximately 42.7% of the calculated $3,162M of notes principal after removing disclosed valuation adjustments. A precise aggregate coupon, the contractual interest rate across those notes, is not separately disclosed. Operating leases also create obligations: the year-end lease table showed $209M of rights to use leased assets and $217M of payment obligations. 10-Q, Note 12; 2025 10-K, Notes 15–16
1-3. Buyback retirements deepened the accumulated deficit
Total equity fell from $14,103M to $13,881M. Paid-in capital, including common stock, declined from $38,722M to $38,711M, while the accumulated deficit widened from $24,278M to $24,326M. Retiring repurchased shares charged $360M against that deficit; it was not an operating loss. The deficit therefore should not be read simply as accumulated business losses. Other accumulated comprehensive losses, which include currency translation adjustments recorded outside net income, increased from $525M to $616M. Assets reconcile to $7,180M of liabilities plus $13,881M of equity. 10-Q, pp. 8, 11
2. Lower transaction costs amplified modest sales growth
Profitability improved, but the earnings increase alone does not establish an equivalent acceleration in underlying demand.
2-1. Lower transaction costs made each sales dollar more profitable
Compare the modest sales increase with the much larger increase in operating profit.
| Item | Q2 2025 | Q2 2026 |
|---|---|---|
| Sales ($M) | 1,749 | 1,819 |
| Operating profit, calculated ($M) | 162 | 256 |
| Operating margin | 9.3% | 14.1% |
| Continuing net income ($M) | 24 | 191 |
| Consolidated net income ($M) | 70 | 147 |
| Continuing net income/sales | 1.4% | 10.5% |
Source: 10-Q, statement of operations, p. 6. Operating profit is sales less reported operating expenses, before affiliate earnings, sundry income and interest; DuPont does not display this subtotal. Continuing net income excludes results classified as discontinued operations, while consolidated net income includes them. Continuing operations can still include costs connected with previously separated businesses.
Operating margin measures the share of sales remaining after operating expenses. Its increase means DuPont generated about $14.10 of operating profit per $100 of sales, versus $9.30; these amounts are neither net income nor cash flow. Acquisition, integration and separation expenses fell from $55M to $7M; a $3M restructuring benefit also helped. Together, these movements explain $51M of the $94M operating-profit increase. 10-Q, p. 6
Excluding only those two expense lines produces $260M versus $217M of operating profit. This limited non-GAAP comparison—an adjustment outside generally accepted accounting principles—adds back transaction expenses and removes the restructuring benefit; it is not a complete measure of recurring earnings. The calculated operating-profit increase of 58.0%, divided by sales growth of 4.0%, gives an operating-leverage ratio of 14.5: profit grew roughly that many times as fast as sales in percentage terms. That historical relationship is distorted by expense removals and is unsuitable as a forecast. These calculations use the statement of operations. 10-Q, p. 6
Interest expense fell from $84M to $41M, providing a separate earnings benefit. Consolidated diluted earnings per share, which account for potentially additional shares, rose from $0.42 to $1.05. Common shareholders’ earnings increased from $59M to $143M; diluted shares fell from 139.9M to 136.8M. Using unrounded divisions, earnings growth explains about $0.60 of the increase and fewer shares about $0.02; rounding explains the remainder. Both periods already reflect the reverse split, which combined existing shares into fewer shares. 10-Q, p. 6; Notes 1 and 8
2-2. The longer record shows an uneven recovery
The recast annual figures, adjusted to reflect the changed business portfolio, show why a strong quarter does not establish a durable peak margin.
| Item ($M unless stated) | FY2023 | FY2024 | FY2025 | Annualized change, 2023–25 |
|---|---|---|---|---|
| Sales, continuing businesses | 6,614 | 6,719 | 6,849 | +1.8% |
| Operating profit, calculated | 36 | 600 | 506 | +274.9% |
| Operating margin | 0.5% | 8.9% | 7.4% | — |
| Continuing net income | −62 | −96 | 98 | Not meaningful |
| Continuing net income/sales | −0.9% | −1.4% | 1.4% | — |
| Consolidated net income | 462 | 738 | −738 | Not meaningful |
| Continuing operating cash | 845 | 765 | 560 | −18.6% |
| Continuing operating cash/net income | −13.63× | −7.97× | 5.71× | — |
Source: 2025 10-K, statements of operations and cash flows, pp. F-6 and F-9. The three observations span two annual intervals; annualized change is (2025/2023)^(1/2) − 1. Negative earnings make cash-conversion ratios economically uninformative.
The low operating-profit base includes a $668M goodwill impairment in 2023, a reduction in the recorded value of acquired businesses. It makes the profit growth rate unsuitable for extrapolation. Comparable continuing-business figures cover only the displayed period; a defensible five-to-ten-year average is not available from these recast statements. Repeated divestitures prevent treating older group results as the same business. 2025 10-K, statement of operations, p. F-6
Quarterly research spending fell from $53M to $42M, while selling and administrative expenses rose from $262M to $269M. These overhead costs do not move directly with each unit sold, but the filing does not fully split fixed and variable costs. Inventory is generally valued using average cost, which averages purchase or production costs, rather than last-in, first-out, the method that expenses the newest inventory first. 10-Q, p. 6; 2025 10-K, Note 1
3. Continuing operations covered first-half payouts only narrowly
Cash reported within continuing operations improved sharply, but cash demands from discontinued operations consumed the remaining cushion. These reporting categories do not perfectly separate current businesses from legacy obligations: some costs connected with separated businesses remain within continuing operations. DuPont Q2 earnings release, basis of presentation
The table includes both continuing and discontinued businesses. H1 means the first six months of the year.
| Item ($M) | H1 2025 | H1 2026 | Change ($M) |
|---|---|---|---|
| Total operating cash | 691 | 474 | −217 |
| Total investing cash | −358 | 983 | +1,341 |
| Total financing cash | −390 | −428 | −38 |
| Ending cash, including restricted cash | 1,879 | 1,782 | −97 |
Source: 10-Q, p. 9. Totals combine the separately disclosed continuing and discontinued cash flows. Exchange-rate effects also enter the full cash reconciliation. Ending balances compare the two June dates, not December with June.
Continuing operating cash rose from $151M to $632M. Receivables consumed $88M rather than $213M, and payables supplied $92M instead of consuming $19M. Together, these changes improved cash generation by $236M. Less cash was tied up in receivables, while amounts owed to suppliers supplied cash; these movements helped cash flow separately from the increase in accounting profit. They do not, by themselves, establish faster customer collections or changed supplier payment terms. 10-Q, cash-flow statement, p. 9
Free cash flow, defined here as operating cash less spending on property and equipment, was $454M: $632M minus $178M. That covered $275M of cash spent on share purchases and forward repurchase contracts—agreements to buy shares later—and $163M of dividends with only $16M remaining. After subtracting $158M of discontinued operating outflows and $6M of discontinued net investing outflows from continuing free cash flow of $454M, $290M remained, below the combined $438M of repurchase-related spending and dividends. The $6M is reported as net cash used for investing activities, not separately identified spending on property and equipment. This calculation therefore does not establish group free cash flow under the operating-cash-flow-minus-capital-spending definition used here. 10-Q, cash-flow statement, p. 9
The first-half total also masks stronger second-quarter cash generation. Continuing operating cash in Q2 was $400M, and capital spending was $76M, leaving $324M under the same free-cash-flow definition. That quarterly improvement matters when assessing whether the first-half funding shortfall will persist. DuPont Q2 earnings release, cash-flow reconciliation
Capital spending was 5.1% of continuing sales, calculated from $178M/$3,500M. The filing does not quantify maintenance versus growth spending. Continuing cash conversion was $632M/$341M, or 1.85 times continuing net income: operating cash exceeded accounting profit within that reporting category. Strong conversion helps, but does not erase the cash obligations left behind by disposed businesses. 10-Q, pp. 6 and 9
4. Healthcare growth coexists with industrial and legal exposure
Sales growth was uneven, while legacy liabilities remained material after the portfolio changes.
Read these product sales as demand indicators; they do not measure product-level profit or isolate currency effects.
| Sales ($M) | Q2 2025 | Q2 2026 | Change |
|---|---|---|---|
| Healthcare Technologies | 444 | 473 | +6.5% |
| Water Technologies | 373 | 383 | +2.7% |
| Industrial Technologies | 513 | 538 | +4.9% |
| Building Technologies | 419 | 425 | +1.4% |
Source: 10-Q, Note 4, p. 20.
Healthcare supplied the fastest sales growth, while building products grew more slowly. Inventory represented approximately 95.4 days of first-half cost of sales: average inventory of $1,191M divided by $2,259M, multiplied by 181 days. This expresses inventory relative to the pace of reported costs; it is a monitoring baseline, not evidence of excess stock without a comparable seasonal history. 10-Q, pp. 6 and 8
The Aramids disposal produced an $82M gain in the quarter when its carrying value was finalized, despite a cumulative $378M disposal loss. The quarterly gain therefore does not establish that the transaction created an equivalent economic profit. 10-Q, Note 3, p. 17
DuPont accrued $125M for North Carolina litigation involving per- and polyfluoroalkyl substances, or PFAS, persistent chemicals involved in environmental contamination claims. An accrual records an expected obligation; it does not mean the cash has already been paid. The filing says additional eligible PFAS losses are reasonably possible but cannot be estimated. Contractual reimbursement rights reduce some exposure, but depend on counterparties meeting their obligations. 10-Q, Note 13, pp. 30–35
On September 10, 2026, after the filing, DuPont announced a North Carolina settlement and said its share was materially covered by existing accruals. Its share had a pretax present value of approximately $126M—the estimated value today of future payments—with 44% to be reimbursed by Qnity Electronics. The settlement provides for payments over 15 years, so the present-value amount is not an immediate cash payment. This narrows uncertainty for the covered claims; it does not resolve every legacy environmental exposure. DuPont’s subsequent settlement announcement
5. Sustainable payouts need cash beyond divestitures
DuPont’s earnings recovery is evident, but recurring cash must carry more of the spending on shareholder returns, investment and legal obligations. Healthcare sales growth and lower operating expenses support earnings; slower building-product sales growth and environmental obligations limit how confidently the quarter can be extrapolated.
Management’s outlook provides a counterweight to the first-half cash shortfall. With its Q2 results, DuPont raised its full-year earnings guidance and forecast organic sales growth slightly above 4%, excluding currency and portfolio changes. It also announced plans to repurchase $250M of shares in Q3. These are management expectations and plans, rather than completed results. DuPont Q2 earnings release
The evidence points to an uneven recovery, rather than an established cycle peak. If cash generation and spending remained at first-half levels, continued buybacks alongside investment and legal payments would require use of accumulated cash or another funding source. Stronger cash generation or lower spending would reduce that need.
Sources: SEC Form 10-Q, filed August 4, 2026; supplemental historical figures from Form 10-K, filed February 17, 2026; DuPont’s August 4, 2026 earnings release; and its September 10, 2026 settlement announcement linked above.
This analysis is based on public filings and the company announcements cited above and is provided for informational purposes only. It is not investment advice.
